Brousseau DC, Duggy SJ, Anderson AC, Linakis JG. Treatment of pediatric migraine headaches. A randomized, double-blind trial of prochlorperazine versus ketorolac. Ann Emerg Med 2004; 43:256-262.
* CLINICAL QUESTION
Is ketorolac more effective than prochlorperazine in the treatment of pediatric migraine in the emergency setting?
* BOTTOM LINE
Prochlorperazine (Compazine) is more effective than ketorolac (Toradol) in the treatment of children presenting to the emergency department with migraine. One additional child will experience headache relief for every 4 children receiving prochlorperazine instead of ketorolac. (LOE=1b)
* STUDY DESIGN
Randomized controlled trial (double-blinded)
* SETTING
Emergency department
* SYNOPSIS
This study is a start in the right direction toward clearing up the lack of information regarding treatment of pediatric migraine in the emergency department. The investigators recruited 62 children aged 5 to 18 years presenting with migraine in either of 2 pediatric emergency departments. Migraine was defined as recurrent headache with at least 3 of the following symptoms: an aura; unilateral location; throbbing pulsatile pain; nausea, vomiting, or abdominal pain; relief after sleep; and a family history of migraine.
Using concealed allocation, researchers randomized patients deemed to require intravenous medication to receive either prochlorperazine 0.15 mg/kg, up to 10 mg, or ketorolac 0.5 mg/kg, up to 30 mg, over 10 minutes. Children not experiencing at least a 50% reduction in pain within 60 minutes were given the alternative study drug and evaluated again.
Using the Nine Faces Pain Scale, 85% of prochlorperazine-treated children and 55% of ketorolac-treated patients experienced at least a 50% relief in pain (number needed to treat [NNT]=4; 95% confidence interval [CI], 2-13). One third of children treated with prochlorperazine achieved complete relief, compared with 7% of children receiving ketorolac (NNT=4; 95% CI, 2-13). Headache recurrence within the following 2 days occurred at a similar rate in both groups (27% and 31%, respectively).
COPYRIGHT 2004 Dowden Health Media, Inc.
COPYRIGHT 2004 Gale Group